Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Liquidia Technologies Announces Expansion of Series C Financing

Abstract:
PPD Joins as New Investor, Increases Series C Financing to $25 Million

Liquidia Technologies Announces Expansion of Series C Financing

Research Triangle Park, NC | Posted on April 20th, 2010

Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that it has added an additional investor, PPD, Inc., to its Series C financing. The final addition of PPD brings the total funding for this round to $25 million. The initial Series C closing was announced in January 2010.

"The vaccines market is one of the fastest growing segments in the industry, and it is an area where PPD has strong laboratory and clinical development expertise," said David L. Grange, Chief Executive Officer of PPD. "Liquidia's novel vaccines and therapeutics have the potential to address a range of diseases, and we believe its PRINT® technology offers a unique solution for improving vaccine safety and efficacy."

PPD, a leading global contract research organization, joins Canaan Partners, New Enterprise Associates, Morningside Venture Investments Limited, Pappas Ventures and Firelake Capital as investors in the Series C round.

"Given PPD's broad expertise in vaccine and biologic drug development, this was a compelling opportunity for both parties," said Neal Fowler, Chief Executive Officer of Liquidia Technologies. "The addition of PPD as an investor provides further resources for rapidly advancing our product pipeline and reinforces the potential of our disruptive technology platform."

Proceeds from the financing will be used to accelerate Liquidia's lead vaccine candidate through initial clinical studies and expand development of particle-based solutions for novel vaccines and therapeutics.

####

About Liquidia Technologies
Liquidia Technologies is developing precisely engineered particles for improved delivery of biological and small molecule therapeutics within the initial fields of vaccines, nucleic acid delivery and inhaled therapeutics. The ability to control particle design parameters such as size, shape and composition is allowing Liquidia to address critical unmet needs in the prevention and treatment of human disease. The company was founded in 2004 and is located in Research Triangle Park, North Carolina.

For more information, please click here

Contacts:
Elle Pishny
919-328-4361

Copyright © Liquidia Technologies

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017

Metal nanoparticles induced visible-light photocatalysis: Mechanisms, applications, ways of promoting catalytic activity and outlook April 27th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

California Research Alliance by BASF establishes more than 25 research projects in three years April 26th, 2017

Investments/IPO's/Splits

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017

Harris & Harris Group Announces the Filing of Preliminary Proxy Materials Detailing Its Proposed Conversion From a BDC to a Registered Closed-End Fund January 24th, 2017

Harris & Harris Group Issues Reminder for Shareholder Update Call on January 10, 2017 January 10th, 2017

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

New Product Nanoparticle preparation from Intertronics with new Thinky NP-100 Nano Pulveriser April 26th, 2017

Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

Announcements

Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017

Metal nanoparticles induced visible-light photocatalysis: Mechanisms, applications, ways of promoting catalytic activity and outlook April 27th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

Video captures bubble-blowing battery in action: Researchers propose how bubbles form, could lead to smaller lithium-air batteries April 26th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project